News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
Experimental MERS Treatments Target Host Cell Receptor
Ashley Yeager | Mar 30, 2017
Researchers are searching for ways to prevent the coronavirus from attaching to DPP-4 receptors, blocking it from invading and replicating within host cells.
Antibody Treatment Lessens Zika’s Effects in Mice
Kerry Grens | Nov 7, 2016
When given to pregnant rodents, a human antibody against a viral envelope protein reduces fetal infection, scientists show.
Cautious Optimism About ZMapp Trial
Bob Grant | Feb 25, 2016
The Ebola drug increased survival in a small study, but the effect was not statistically significant.
Single Antibody Protects Macaques from Ebola
Amanda B. Keener | Feb 25, 2016
The “just right” binding properties of a monoclonal antibody from an Ebolavirus survivor help it neutralize the virus.
In Situ Antibodies
Jyoti Madhusoodanan | Feb 2, 2016
Compared with systemic injections, localized antibody therapies may be more effective for some indications.
Paul Ko Ferrigno, Jane McLeod | Feb 1, 2016
Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.
Exercises for Your Abs
Amber Dance | Feb 1, 2016
Companies make the antibodies, but it’s up to you to make sure they work in your experiments.
Building Better Reagents
Jane McLeod, Paul Ko Ferrigno | Feb 1, 2016
Facing problems of inconsistent, time-consuming, and costly antibody production, some researchers are turning to alternatives to target specific proteins of interest, in the lab and in the clinic.
Amyloid-Targeting Immunotherapy Disrupts Neuronal Function
Karen Zusi | Nov 9, 2015
Some antibodies designed to eliminate the plaques prominent in Alzheimer’s disease can aggravate neuronal hyperactivity in mice.
Two-Faced Proteins May Tackle HIV Reservoirs
Amanda B. Keener | Oct 21, 2015
Researchers design antibody-like proteins to awaken and destroy HIV holdouts.